As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...
The field of nanomedicine is rapidly advancing, offering significant potential to revolutionize oral health care. By operating at the nanoscale, researchers have developed innovative technologies with ...